Russia’s public health watchdog Rospotrebnadzor affirmed on Tuesday that the EpiVacCorona COVID-19 vaccine, the second jab that Moscow recorded, has proved a 100% efficacy in the clinical trials.
The evaluation was based on the data collected during the first two phases of the jab’s clinical trial, the statement read.
The vaccine, developed by the Vector Institute, was filed in October and entered the third phase of the trial a month later.
Solidarity with Gaza is apparent at universities around the globe, with student movements in France,…
The Ministry of the Interior declared, in an official press release, that security units in…
The prosecution at the Ariana Court of First Instance authorized agents of the Ariana North…
Labour's Sadiq Khan has won a third successive term as mayor of London. Khan defeated…
The civil society components of Al-Amra, in partnership with some organizations from the delegations of…
A joint patrol between the different specialities of the Monastir National Guard district was able…
This website uses cookies.